JBC:中科院上海药物所徐华强课题组等发现B型GPCR激活新机制

2017-04-07 佚名 生物帮

近日,国际知名生物化学杂志《Journal of BioLogical Chemistry》在线发表了中国科学院上海药物研究所徐华强课题组与王明伟课题组合作研究论文,研究论文题为Rearrangement of a polar core provides a conserved mechanism for constitutive activation of class B G protein-c

近日,国际知名生物化学杂志《Journal of BioLogical Chemistry》在线发表了中国科学院上海药物研究所徐华强课题组与王明伟课题组合作研究论文,研究论文题为Rearrangement of a polar core provides a conserved mechanism for constitutive activation of class B G protein-coupled receptors,研究论文发现了B型g蛋白偶联受体(G protein-coupled receptor, GPCR)新的激活机制。徐华强课题组博士殷艳婷为论文的第一作者,通讯作者为徐华强及王明伟。

B型分泌素GPCR家族由15种肽类激素受体组成,包括胰高血糖素受体、血管活性肠肽受体、胰高血糖素样肽受体和甲状旁腺激素受体等,在体内激素平衡调节中发挥关键作用,是治疗骨类疾病、代谢性疾病和神经系统疾病的重要药物作用靶标。由于目前对该家族受体的激活机制及构象变化知之甚少,基于其下游信号通路的药物开发举步维艰。

研究工作以胰高血糖素受体为研究对象,提出了其激活的分子机制,即受体第六跨膜区被保守极性口袋和疏水区域限制在非活性构象,破坏这两个关键结构域会使第六跨膜区的构象发生改变从而产生自我激活效应。研究人员还发现,该保守极性口袋的重组也会导致其他B型GPCR(如血管活性肠肽受体I、促肾上腺皮质激素释放因子受体I、甲状旁腺激素受体I和垂体腺苷酸环化酶激活多肽受体I等)的自我激活,说明重组该保守极性口袋为B型GPCR的共有激活机制。

研究成果也解释了人们20年前所观察到的现象,即为何甲状旁腺激素受体中的双位点突变会引起受体发生自我激活而导致Jansen’s Metaphyseal Chondrodysplasia(一种先天性软骨发育异常症)。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1658644, encodeId=2319165864462, content=<a href='/topic/show?id=95d0819851' target=_blank style='color:#2F92EE;'>#GPCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8198, encryptionId=95d0819851, topicName=GPCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=646024894629, createdName=马龙, createdTime=Fri Nov 24 00:43:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972166, encodeId=73e619e2166c1, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Jan 04 00:43:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862583, encodeId=14821862583cd, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 19 21:43:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036435, encodeId=a2e620364358a, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Oct 18 01:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419384, encodeId=00881419384eb, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sun Apr 09 11:43:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]
    2017-11-24 马龙
  2. [GetPortalCommentsPageByObjectIdResponse(id=1658644, encodeId=2319165864462, content=<a href='/topic/show?id=95d0819851' target=_blank style='color:#2F92EE;'>#GPCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8198, encryptionId=95d0819851, topicName=GPCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=646024894629, createdName=马龙, createdTime=Fri Nov 24 00:43:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972166, encodeId=73e619e2166c1, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Jan 04 00:43:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862583, encodeId=14821862583cd, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 19 21:43:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036435, encodeId=a2e620364358a, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Oct 18 01:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419384, encodeId=00881419384eb, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sun Apr 09 11:43:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1658644, encodeId=2319165864462, content=<a href='/topic/show?id=95d0819851' target=_blank style='color:#2F92EE;'>#GPCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8198, encryptionId=95d0819851, topicName=GPCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=646024894629, createdName=马龙, createdTime=Fri Nov 24 00:43:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972166, encodeId=73e619e2166c1, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Jan 04 00:43:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862583, encodeId=14821862583cd, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 19 21:43:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036435, encodeId=a2e620364358a, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Oct 18 01:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419384, encodeId=00881419384eb, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sun Apr 09 11:43:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]
    2017-11-19 gous
  4. [GetPortalCommentsPageByObjectIdResponse(id=1658644, encodeId=2319165864462, content=<a href='/topic/show?id=95d0819851' target=_blank style='color:#2F92EE;'>#GPCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8198, encryptionId=95d0819851, topicName=GPCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=646024894629, createdName=马龙, createdTime=Fri Nov 24 00:43:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972166, encodeId=73e619e2166c1, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Jan 04 00:43:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862583, encodeId=14821862583cd, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 19 21:43:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036435, encodeId=a2e620364358a, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Oct 18 01:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419384, encodeId=00881419384eb, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sun Apr 09 11:43:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]
    2017-10-18 lily1616
  5. [GetPortalCommentsPageByObjectIdResponse(id=1658644, encodeId=2319165864462, content=<a href='/topic/show?id=95d0819851' target=_blank style='color:#2F92EE;'>#GPCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8198, encryptionId=95d0819851, topicName=GPCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=646024894629, createdName=马龙, createdTime=Fri Nov 24 00:43:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972166, encodeId=73e619e2166c1, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Jan 04 00:43:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862583, encodeId=14821862583cd, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 19 21:43:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036435, encodeId=a2e620364358a, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Oct 18 01:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419384, encodeId=00881419384eb, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Sun Apr 09 11:43:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]
    2017-04-09 Tommy1950

相关资讯

J.Immunol.:自身免疫病相关新药物作用靶点GPCR

G蛋白偶联受体(GPCR)是一类重要的药物作用靶点,目前市场上有超过40%的药物是通过作用于GPCR起到治疗作用。人体大约有800-1000个GPCR,发现GPCR在重大疾病中的新作用可以为疾病治疗提供新药靶或新方法。 多发性硬化(Multiple sclerosis,MS)是一种与神经系统相关的自身免疫性疾病,是仅次于创伤的中青年人致残原因,目前尚缺乏有效的治疗药物,有着“死不了的癌症”之称。

Circ Res:20-HETE影响血管功能、触发高血压

20-羟基二十碳四烯酸(20-HETE)是细胞色素P450类花生酸之一,是一种有效的血管活性脂质,其血管作用包括促进平滑肌细胞收缩,迁移和增殖,并与内皮细胞功能障碍和炎症相关。实验动物和人体中20-HETE水平升高与高血压,中风,心肌梗死和血管疾病等相关。近来来自纽约医科大学的学者发表研究型文章《20-羟基二十碳四烯酸信号通过G蛋白偶联受体GPR75(Gq)影响血管功能、触发高血压》于著名血管杂志